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Alexander Licht4, Marina Schorpp-Kistner4, Peter Angel4 and Cornelia Mauch1
Tumor invasion and metastasis of malignant melanoma have been shown to require proteolytic degradation of
the extracellular environment achieved primarily by enzymes of the matrix metalloproteinases (MMP) family.
We have earlier shown that increased enzyme activity is localized at the border of tumor cells and the adjacent
peritumoral connective tissue, emphasizing the importance of tumor-stroma interactions in the regulation of
MMP activity. To confirm the role of stroma-derived MMP-13 in the invasion process, we investigated the
invasiveness of melanoma cells upon intradermal injection in mice with complete inactivation of MMP-13.
Tumor growth was significantly impaired in mmp-13/ mice and most significant at early time points as
compared with wild-type littermates. Moreover, metastasis to various organs was reduced to 17.6 vs 30% in
lungs, 2.9 vs 30% in the liver. Strikingly, ablation of MMP-13 completely abrogated formation of metastasis in the
heart (0 vs 40%). Notably, decreased tumor growth in mmp-13/mice was associated with reduced blood vessel
density. In addition, decreased blood vessel permeability in the tumors was measured by magnetic resonance
imaging of tumor-bearing animals. These data suggest an important role of MMP-13 in tumor growth and an
unexpected role in organ-specific metastasis of melanoma cells.
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INTRODUCTION
Degradation and/or remodeling of matrix components is one
of the events necessary for melanoma cell invasion through
tissues and it is accomplished by the concerted action of
different proteases. The best-characterized proteases in this
process are the matrix metalloproteinases (MMP). In normal
tissues, basal expression and activity of MMPs is almost
absent. However, under certain physiological as well as in
pathological conditions, different factors have been shown to
modulate the expression and activity of MMPs, such as
contact of the cells with extracellular matrix (ECM) compo-
nents and the release of cytokines and growth factors (Itoh
et al., 1995; Wandel et al., 2000; Loffek et al., 2005). Also,
several growth factors (EGF, PDGF, bFGF, VEGF) and
cytokines (for example, IL-1, IL-6, TNF-a, TGF-b) are secreted
by tumor-infiltrating inflammatory cells as well as by tumor or
stromal cells and can modulate de novo synthesis of MMPs.
The proposed role of MMPs in tumor invasion is mainly
based on the observation of high-level expression of
distinct MMPs in invasive malignant tumors (reviewed by
Westermarck and Kahari, 1999). It is widely accepted that
collagenases play an important role in the cleavage of the
interstitial fibrillar collagens of types I, II, and III. Therefore,
degradation of collagenous ECM by these MMPs is likely to
be essential for invasion of malignant cells and tumor-
associated neovascularization. For instance, mice lacking
MMP-7 revealed reduction in intestinal tumorigenesis
(Wilson et al., 1997) and MMP-2-deficient mice show reduced
angiogenesis and tumor progression (Itoh et al., 1998).
Several recent investigations have shown that in various
human carcinomas expression of MMPs is localized to both
tumor and stromal cells at the invading margin of the tumor,
providing a mechanism for highly concerted degradation of
ECM. In human melanoma, MMP-1 protein has been
localized to stromal fibroblasts adjacent to the tumor cells,
whereas tumor cells and fibroblasts distant to the tumor site
stained negative for MMP-1 (Airola et al., 1999). A different
distribution has been shown for the expression of MMP-14
and 13. Immunohistochemical analysis of melanoma tissue
has shown that MMP-2 and MMP-14 and their inhibitors
TIMP-1 and -2 are detected within the tumor and the
surrounding stroma (Kurschat et al., 2002). Although in
breast carcinoma, MMP-13 was found to be expressed
primarily by stromal fibroblasts, in squamous cell carcinoma,
it was predominantly confined to the tumor cells (Airola
See related commentary on pg 2545ORIGINAL ARTICLE
2686 Journal of Investigative Dermatology (2009), Volume 129 & 2009 The Society for Investigative Dermatology
Received 10 November 2008; revised 13 February 2009; accepted 2 April
2009; published online 11 June 2009
1Department of Dermatology and Center for Molecular Medicine (CMMC),
University of Cologne, Cologne, Germany; 2Department of Medical Physics
in Radiology, Heidelberg, Germany; 3Department of Microbiology,
University of Virginia, Virginia, USA and 4Division of Signal Transduction and
Growth Control, Heidelberg, Germany
Correspondence: Dr Cornelia Mauch, Department of Dermatology,
University of Cologne, Kerpener Str. 62, Cologne 50931, Germany.
E-mail: Cornelia.Mauch@uk-koeln.de
Abbreviations: MMP, matrix metalloproteinase; MT-MMP, membrane-type
matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; WT,
wild-type; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast
growth factor; PDGF, platelet derived growth factor; EGF, epidermal growth
factor; IL-, interleukin; TNF, tumor necrosis factor; TGF-b, transforming
growth factor
et al., 1997). As MMP-1 is not produced in the murine
system, MMP-13 and MMP-14 most likely represent the main
collagenases in mice.
Mouse MMP-13 has been demonstrated to play an
important role in skeletal development (Stickens et al., 2004).
During tumor growth and progression of breast cancer a
prominent upregulation of mouse MMP-13 was observed in
the stroma (Lafleur et al., 2005). However, skin homeostasis
and cutaneous wound healing are independent of MMP-13
likely due to functional compensation by MMP-8
(Hartenstein et al., 2006).
Using mice carrying a complete inactivation of the mmp-
13 gene, we have addressed the role of stroma-derived MMP-
13 for the development of melanoma grafts in vivo. Further,
we demonstrated that development and metastasis of
melanoma in vivo depends greatly on the expression of
MMP-13 in the peritumoral area. The impaired tumor growth
and metastasis in MMP-13-deficient mice may be attributed
at least partially to reduced tumor angiogenesis.
RESULTS
MMP-13 is expressed in endothelial cells of B16F1 grafts in vivo
Under physiological conditions, expression of MMP-13 is
almost absent in murine skin (Madlener et al., 1998;
Hartenstein et al., 2006). In agreement with these data,
analysis of MMP-13 transcripts in unaffected murine skin
shows no amplification product from RNA extracted from
complete skin upon reverse transcription (RT)–PCR amplifica-
tion (Figure 1a). A strong induction of MMP-13 mRNA
transcripts was observed in B16 tumors developing in wild-
type (WT) animals 10 days post-tumor cell injection, whereas
expression of MMP-13 transcripts was completely absent in
B16 tumors generated in knockout animals. These data
indicate that expression of MMP-13 is not induced in tumor
cells but rather in the tumor-activated stromal compartment.
The expression of the second main collagenase in mice, MMP-
14 was similar for WT and mmp13/ animals (Figure 1b).
Immunohistological examination of the B16F1 tumors
raised in WT mice show expression of MMP-13 mainly in the
stromal areas proximal to melanoma cell invasion (Figure 2a,
s, stroma; t, tumor). Small MMP13-positive local spots were
also observed in the peripheral tumor mass (Figure 2, tumor)
and in few intratumoral cells. Tumor cells were identified by
staining for the tyrosinase-related protein-1 (Figure 2a, TRP-1).
These data together with the transcript analysis suggest an
importance for stromally derived MMP-13 for melanoma
growth in vivo. Confocal analysis depicted expression of
MMP-13 in the cytoplasm of CD31-positive cells with a
polarized distribution toward the vessel lumen where it is
likely to be secreted (Figure 2b, A0). Expression of MMP-13
was found in smooth muscle actin-positive cells (B and B0;
SMA, red) surrounding the vessel, whereas no MMP-13
expression was observed in tumor-infiltrating neutrophils
(Figure 2b, C and C0). Interestingly, some but not all CD68-
positive macrophages also showed a strong cytoplasmic
staining for MMP-13 (Figure 2b; D and white arrows in D0).
Host-derived MMP-13 is important for the growth and
metastasis of melanoma in vivo
To analyze the influence of stroma-derived MMP-13 expres-
sion in peritumoral areas on the development of melanoma
in vivo, we have grafted B16F1 melanoma cells by
intradermal injection into the flank of WT and mmp-13/
animals. Tumor growth was measured as a function of time.
Measurable B16F1 melanomas were detected as early as at
day 2 post-injection and reached an average size of 600mm3
10 days post-injection (Figure 3a). In contrast, depletion of
stromal MMP-13 significantly inhibited tumor growth. In
MMP-13 null mice, melanomas were only visible and
measurable at day 4 and had a strikingly reduced average
size of 300 cm3 after 10 days as compared with injected
littermate controls (Figure 3a).
In parallel, we have analyzed metastasis formation 9 days
post-injection by RT–PCR analysis of mRNA from different
isolated organs for the expression of GFP transcripts solely
expressed from GFP-tagged melanoma cells. This analysis
revealed a consistent reduction in the overall metastasis to
the lungs, liver, and brain of the mmp-13/ animals (Figure
3b). Comparison of WT and mmp-13/ animals showed
reduced metastases in mmp-13/ mice as compared with
control littermates in 17.6 vs 30% of the lungs, 2.9 vs 30% in
the liver, and 11.8 vs 30% in the brain. The most significant
difference was associated with metastasis to the hearts. No
metastasis was found in hearts from mmp-13/ as compared
with WT animals, where melanoma cells infiltrated 40% of
the hearts.
Lack of MMP-13 results in reduced tumor growth and invasion
due to inhibition of angiogenesis but not of the inflammatory
reaction
MMP-13 expression was observed in CD31 and some CD68
positive cells (Figure 2, A0 and D0, arrows) suggesting that
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Figure 1. Matrix metalloproteinases (MMP)-13 is produced by tumor-
activated stroma. B16F1-GFP melanoma cells were injected intrademally in
wild-type (WT) or knockout MMP-13 mice (mmp-13/) and allowed to grow
for 10 days. (b) Primary tumors grown in three different WT and mmp-13/
mice, numbered from 1 to 3, or normal unaffected skin (a) were prepared.
RNA was isolated from all tissues and reverse transcription–PCR was
performed as described in ‘‘Materials and Methods’’ section. GFP
amplification was used to identify of B16F1 melanoma cells, whereas S26 was
used as loading control. Note that MMP-13 transcripts were amplified in
tumors from WT animals but not from those grown in mmp-13/ animals.
MMP-14 was amplified in both extracts.
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MMP-13 expression may contribute to both neo-angiogenesis
and infiltration by macrophages during tumor development.
Presently it is unclear which type of tumor-associated
macrophage expresses MMP-13. As the tumor growth was
consistently impaired in mmp13/ mice and was already
visible as early as day 4 post-injection, it is conceivable that
either angiogenesis and macrophage homing or phenotypic
differentiation or altogether might be altered at this early time
point.
Analysis of macrophage (CD68 positive) as well as
neutrophil infiltration in day 4 tumors of mmp13/ and
WT mice, failed to show any remarkable difference in cell
density and homing (Figure 4). Similar data were observed
with leukocytes (data not shown). On the contrary, analysis of
CD31 positive vessels in tumors showed a strong reduction of
vessel density in the peritumoral areas of mmp-13/ at day 4
(Figure 5). In addition, in the absence of host-derived MMP-
13 a dramatic decrease in vessels penetrating into the
peripheral tumor area was observed. However, few intratu-
moral CD31 positive vessels were still present (Figure 5a,
tumor margin is marked by a dotted line).
In addition, quantification of number of CD31 and LYVE-
stained vessels at day 4 of melanoma development,
confirmed that density of blood (Figure 5b) but not lymphatic
vessels (data not shown) was significantly decreased in mmp-
13/ animals bearing B16 tumors (Po0.0001). Furthermore,
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Figure 2. Matrix metalloproteinases (MMP)-13 is expressed within the tumor and in peritumoral cells. (a) Analysis of MMP-13 (red) and TRP-1 (tyrosinase-
related protein-1, red) expression by immunohistochemistry in B16F1 tumors developed in wild-type animals. Black and white pictures of single MMP-13
and TRP-1 staining are shown on the right. Cellular nuclei are stained in blue. The upper pictures represent MMP-13 and control IgG immunodetection in B16F1
tumors, followed by chromogenic development. MMP-13-positive areas are shown in red. t, tumor; s, stroma. MMP-13 is detected in the peritumoral stroma,
as shown by both staining methods, and within the periphery of the tumor mass. Scale bar¼ 100 mm. (b) Immunostaining of MMP-13 (red, only in B it is
green) in the tumors of wild-type animals. A, counterstaining of blood vessels (CD31, green); B, smooth muscle actin-positive cells (SMA, red); C, neutrophils
(neutro, green), and D, macrophages (CD68, green). MMP-13-positive CD31 and CD68 cells are indicated by the white arrows. Blue stain corresponds to nuclei.
The lower microphotographs, A0–D0 are details of the above shown confocal images (scale bar¼ 100mm A–D; scale bar¼15 mm A0–D0).
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while MMP-13 expression was absent in mmp-13/ animals
in tumor and stroma, in WT animals strong expression is
appearing in the tumor and peritumoral stroma concomi-
tantly with the induction of angiogenic response (Figure 5a,
white arrows).
Lack of MMP-13 inhibits tumor growth and invasion by
inhibiting de novo-induced tumor angiogenesis
Vascular leakage is present in pathological angiogenesis as
observed in retinopathy and also during tumor development
(Timar et al., 2001). To analyze whether reduction in blood
vessel density also results in alteration of intra-tumoral blood
volume and vessel permeability, we have used in vivo
dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) according to a pharmacokinetic two-compart-
ment model. This method described by Brix et al. (1991)
allows to determine the parameters Amplitude, A, which is a
measure of blood volume and exchange rate constant, kep,
which is associated with vessel permeability in animals
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Figure 3. Kinetics of the growth of B16F1 grafts and metastasis in wild-type
and mmp-13/ animals. (a) Tumor sizes (mm3) were measured as function of
time after intradermal injection of B16 melanoma cells in wild-type (WT) and
mmp-13/ mice. Data were expressed as average±SEM; n represents the
number of animals per group. Hematoxilin-eosin staining of sections from
tumors at day 4 post-injection is shown (when the divergence of tumor growth
is most significant) Scale bar¼100 mm. **Po0.0057 and *Po0.01.
(b) Reverse transcription–PCR amplification of the GFP gene was used to
detect B16F1 melanoma cells in the various dissected organs at day 11 after
intradermal injection of B16F1 melanoma cells in wild-type (wt) and
mmp-13/ mice. Numbers of positive amplified signals are expressed as
number of positive animals on the total number analyzed and below as
percentage of the analyzed organs.
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Figure 4. Neutrophil and macrophages are recruited around the tumors.
Immunostaining of neutrophils and macrophages CD68 (both in green) of
cryosections from B16F1 skin tumors from mmp-13/ and wild-type (WT)
animals. Scale bar¼ 100mm.
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Figure 5. Angiogenesis and tumor infiltration. (a) Analysis of angiogenesis
and vascularization of B16F1 grafts at day 4 post-injection of wild-type (WT)
and mmp-13/ animals. Immunostaining of CD31-positive endothelial cells
(green) and MMP-13 (red) positive peritumoral and tumor areas. White arrows
indicate areas where MMP-13 is expressed. Nuclei were stained by DAPI
(blue). The dotted line delineates the tumor. On the right panel, black and
white microphotographs of MMP-13 immunodetection are shown. Scale
bar¼ 100 mm. (b) Quantification of stromal angiogenesis and tumor
vascularization confirms the reduced angiogenic response in the entire tissue,
bars represent the average number of blood vessels±SEM of three 100
magnification fields per section taken in the middle, half, and end of the
tumor from each of four animals. ***Po0.001.
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carrying grafted tumors. In inoculated WT animals the
parameters A (NS), which is a surrogate parameter for blood
volume and kep (Po0.02), which is associated with vessel
permeability, were decreased in tumors of mmp-13/ mice
compared with controls (Figure 6). Thus, the observed
reduction in blood vessel permeability together with the
reduced CD31 staining observed in the tumor periphery
(Figure 5) collectively show a reduction of angiogenetic
processes around the tumors in mmp-13/ mice.
DISCUSSION
Expression of proteolytic enzymes during the progression of
cancer has been consistently associated with poor prognosis
in a variety of cancers. Matrix metalloproteinases are
believed to mediate tumor invasion through several mechan-
isms, including activation of other enzymes, processing of
matrix components to modulate cell migration, and release of
bioactive factors bound to the ECM. In addition, crosstalk
between tumor and stromal cells is known to also induce
protease production by one or both cell types (Gallagher
et al., 2005; Zigrino et al., 2005). However, the molecular
mechanisms by which these enzymes contribute to the
progression of this tumor in vivo are still a matter of
investigation.
Of all collagenolytic enzymes only expression of MMP-1
and MMP-13 mRNA has been found to correlate with
melanoma progression and early metastasis (Airola et al.,
1999; Nikkola et al., 2001; Kuivanen et al., 2005), and
expression of MMP-13 is believed to promote tumor
development in other type of cancers (Kahari et al., 1998;
Nielsen et al., 2001; Zhang et al., 2008). The cellular source
and role of MMP-13 appears to be different depending on the
type of tumor analyzed.
In breast cancer, Zhang et al. (2008) suggested that only
tumor-derived, but not stromal fibroblast-derived, MMP-13
correlated with aggressive tumor phenotypes. In agreement,
in invasive and metastatic human skin tumors, MMP-13
expression was predominantly confined to the tumor cells
(Airola et al., 1999), whereas its expression was absent in
normal dermis and benign pigmented lesions.
Conversely, in mouse models for squamous-cell carcino-
mas and in breast cancer xenografts, a prominent upregula-
tion of MMP-13 was observed in the host stroma (Lafleur
et al., 2005; Akgul et al., 2006). Consistent with these data,
we could show a strong expression of mouse MMP-13 in the
stroma surrounding B16F1 tumors as well as in few
intratumoral cells. This is in agreement with the lack
amplification of MMP-13 from tumors developed in WT
animals (Figure 1), thus implying that MMP-13 is derived
from tumor-infiltrating stromal cells. However, Corte et al.
(2005) have detected MMP-13 in tumor cells in 30% of in situ
melanomas. Thus, it is possible that expression of MMP-13 by
stromal cells may be necessary to direct toward a malignant
phenotype in a specific and narrow time frame. In agreement
with this hypothesis are the data showing that stroma-derived
MMP-13 was induced only when a differentiated human
premalignant epithelium shifted to a malignant and invasive
tumor phenotype (Vosseler et al., 2005).
On the basis of these data we have used a mouse model
where expression of host-derived MMP-13 is abolished in
order to identify specific functions for this protease during
melanoma development in vivo. Indeed, depletion of MMP-
13 resulted in a significant reduction in tumor growth and
metastasis formation. The complete lack of metastasis to the
heart is presently not understood and suggests a specific role
of MMP-13 in modifying adhesion molecules, homing
receptors, or the matrix of this tissue. Ongoing proteomic
analysis may unravel the mechanisms of this finding. When
analyzing the kinetics of tumor growth in the WT versus the
mmp-13/ animals, a clear difference in tumor growth was
visible already at earlier time points thus indicating a critical
role of MMP-13 in the early stage of tumor formation. For the
progression from a benign to a malignant phenotype,
melanoma requires cross communication with stroma as
well as the creation of an inflammatory milieu (Zigrino et al.,
2005). In the present model of melanoma, the influence of
neutrophils, macrophages, and leukocytes (not shown) was
not altered suggesting that influx of inflammatory cells does
not depend on MMP-13 and that modulation of the
inflammatory reaction is not responsible for the observed
differences in tumor growth.
In addition to a significant reduction of vessel formation,
infiltration of blood vessels into the tumor mass and thus
tumor vascularization was dramatically reduced in the
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Figure 6. Stromal depletion of matrix metalloproteinases (MMP)-13 leads to
a reduction in DCE-MRI parameters A and kep. From dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI) the parameters amplitude
(A) and exchange rate constant (kep) were assessed of the tumors developed in
wild-type (WT) and mmp-13/ mice at day 6 post-injection. In the upper
panel axial MRI images of mice are shown with color maps of parameters
analyzed in the tumors are shown. Tumors developed in mmp-13/ animals
showed significantly lower kep values (*Po0.02; surrogate parameter for
vessel permeability) than the WT control tumors whereas no significant
difference in the parameter A (surrogate parameter for blood volume) was
detected (left graph).
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absence of host MMP-13. Zijlstra et al. (2004) have identified
MMP-13 as one of the collagenases responsible for collagen
remodeling associated with angiogenesis, thus implying that
MMP-13 in angiogenesis may be necessary for cellular
migration rather than participating in the VEGF/VEGFR
cascade. In agreement with these data we have failed to
see any significant difference in the levels of VEGF in extracts
from the tumors (data not shown).
The crucial role of MMP-13 in promoting and maintaining
angiogenesis is further supported by the localization of MMP-
13 in close proximity to newly formed blood vessels. New
blood vessel formation in a chorioallantoic membrane assay
is dependent on the collagenolytic activity of macrophage-
derived chMMP-13 (Zijlstra et al., 2004). In addition,
macrophages have also been shown to produce MMP-13,
which they use to resorb the interstitial matrix and success-
fully remodel the fibrotic liver (Fallowfield et al., 2007).
Other cells implicated in MMP-13 production are neutro-
phils, which were shown to secrete MMP-9 and MMP-13
thereby modulating angiogenesis, by remodeling the ECM
(Obermueller et al., 2004). We have detected both cell types
in the peritumoral stroma of melanoma grafts, and MMP-13
production was detected in only a few macrophages.
The MMP-13 expression colocalized with CD31 staining
cells, strongly suggesting that endothelial cells are an
important cellular source of this protease. This finding is
supported by the observation that MMP-13 in endothelial
cells is polarized toward the vessel lumina thus indicating a
secretory activity.
Interestingly, active MMP-13 was found in serum in
melanoma patients (Nikkola et al., 2005). Furthermore,
serum levels of MMP-13 have been associated with severity
of systemic sclerosis (Asano et al., 2006). However, whether
this may represent a clearing path for depletion of the enzyme
or a distribution way is presently unclear. Further studies are
ongoing to clarify whether the secretion of MMP-13 may
contribute to metastasis formation.
Tumor vessels are characterized by their disorganized
structure with a low maturity and a high degree of vessel
permeability (Metheny-Barlow and Li, 2003). In mmp-13/
mice, vessel permeability was reduced as suggested by the
MRI measurements, where a significant kep was observed. It is
possible that not all vessels visualized in tumors by
immunostaining are really functional and perfused. Thus,
the blood volume may be equal in tissues with few large
vessels as compared with those with many small vessels.
However, decreased blood vessel density during tumor
growth in mmp-13/ mice paralleled the decreased blood
vessel permeability in vivo, as detected by MRI of tumor-
bearing animals. Therefore, we can assume that reduced
perfusion in mmp-13/ mice is the result of reduced
angiogenesis. In addition, reduced angiogenesis and most
likely reduced proteolysis in the proximity of these vessels
may account for the reduced percentage of metastasis
through the hematogenous pathway. As we failed to see
differences in the levels of several proangiogenetic factors (for
example, VEGF, bFGF, IL-1, data not shown) in the extracts
from tumors of WT and mmp-13/ animals, we hypothesize
that lack of matrix proteolysis from ‘‘invading’’ endothelial
cells may be responsible for reduced angiogenesis and
intratumoral vascularization. The reduced availability of
vessels may also lead to reduction of tumor cells spreading
in the organism.
These data together implicate MMP-13 in melanoma
growth and reveal an unexpected role for this protease in
organ-specific metastasis of melanoma cells and in patholo-
gical angiogenesis.
MATERIALS AND METHODS
Transgenic animals
The mmp-13/ mice in a C57BL/6 background (backcrossed for 10
generations) were generated and genotyped by PCR and Southern
blot as described earlier (Hartenstein et al., 2006). All animal
experiments were performed in accordance with the Institutional
Guidelines.
Tumorigenicity assay in vivo
B16-F1 cells (1 106) in 100 ml were injected intradermally into the
flank of 6- to 8-week-old WT (floxed mmp-13/) and mmp-13/
littermate mice. Tumor size was measured every 2 days using a
precision calliper up to 14 days. Tumor volume was calculated by
multiplying length, width, depth and expressed as average±SEM.
The animal experiments have been approved by the local veterinary
authority (NRW authorization 50.203.2-K 37a, 20/05).
RT–PCR analysis
Total DNase-treated RNA from the various organs was prepared
using the RNAeasy Fibrous tissue Kit following the manufacturer’s
instructions (Qiagen, Germany). RT–PCR was performed according
to the manufacturer’s instructions (REDTaq ReadyMix PCR Reaction
Mix, Sigma, Taufkirchen, Germany). Briefly, 1 mg RNA was reverse
transcribed using oligo dT as primer in a total volume of 25 ml. A
volume of 2ml of the cDNA was used to amplify specific transcripts by
PCR. Primers for the amplification of murine MMP-13 and MMP-14
were elsewhere described (Kim et al., 2000). The following primers
were used for amplification of murine S26: 50-AATGTGCAGCCC
ATTCGCTG and 50-CTTCCGTCCTTACAAAACGG (NM013765); GFP:
50-ACCCCGACCACATGAAGCAGC and 50-CGTTGGGGTC
TTTGCTCAGGG. PCRs were performed on 1 ml cDNA for 35–38
cycles (within the linear range of amplification): denaturation (941C,
1minute), annealing (561C, 1minute), and extension (721C,
1minute). The products were then analyzed on 2% agarose gels in
Tris-borate-EDTA.
Histological analysis and indirect immunofluorescence staining
of skin sections
Tumor samples at the indicated time points were snap-frozen in
optimal-cutting-temperature compound (O.C.T. Tissue Tec) and
cryosectioned (7 mm). Immunostaining to detect MMP-13 (Santa
Cruz Biotechnology, Heidelberg, Germany), melanoma antigen
(tyrosinase-related protein-1, TRP-1; Santa Cruz Biotechnology),
smooth muscle actin (SMA; Cy3-conjugated; Sigma), macrophages
(CD68) and neutrophils (anti-neutrophils; Serotec, Du¨sseldorf,
Germany), endothelial cells (CD31, Pharmingen, Heidelberg,
Germany), and polymorphonuclear cells (CD45) was performed
as described earlier (Hartenstein et al., 2006) and examined
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with a Nikon Eclipse 800 fluorescence microscope equipped with a
DXM1200 digital camera. In addition, anti-MMP-13 antibodies were
also detected using a peroxidase-conjugated secondary antibody
and chromogenic development using Envision system (DAKO).
Analysis of blood vessel density
For assessment of the tumor vessel count, different fields in each
section (taken from central, intermediate and peripheral part of the
tumor) were examined. Quantification was performed using ImageJ
software (http://rsb.info.nih.gov/ij). The mean number of CD31-
positive vessels was calculated from three 100 magnification
fields per section (from five different sections per animal) of four
different animals per time point according to the published protocols
(Eikesdal et al., 2008; Xue et al., 2008).
Dynamic contrast-enhanced MRI
Dynamic contrast-enhanced MRI was performed on a clinical 1.5-
Tesla whole-body MRI system (Siemens Symphony, Erlangen,
Germany) using a custom-made radiofrequency coil (animal
resonator) (Kiessling et al., 2003). The MRI sequence was a T1-
weighted inversion recovery turbo flash sequence (TR 13ms, TE
5.3ms, TI 300ms, slice thickness 2mm, FOV 60 60mm2, Matrix
128, orientation axial). For examination and catheterization, WT or
mmp-13/ mice (five per group) bearing a 6 days old B16
melanoma graft, were anesthetized by inhalation of a mixture of
isofluorane (1.5%), N2O (35%), and O2 (60%). A tail vein was
catheterized using a 30-gauge needle connected to a 10-cm-long
phycoerythrin 10 polyethylene catheter (Portex, Medic-Eschmann,
Germany) filled with 10ml of 0.9% NaCl. The needle was fixed on the
mouse tail with superglue. The distal end of the catheter was connected
with a 1-ml tuberculin syringe, both containing MRI contrast media
(gadolinium diethylenetriaminepentaacetic acid, Gd-DTPA; Magnevist
Schering, Berlin, Germany). MRI contrast media (0.1mmol Gd-DTPA
per kg diluted in 0.9% NaCl to a total volume of 100ml) was injected
manually within 5 seconds into the tail vein of mice.
Analysis of the dynamic data was based on the pharmacokinetic
two-compartment model of Brix et al. (1991), where compartment 1
is defined as the intravascular extracellular space and compartment
2 as the extravascular extracellular space. After infusion of the
contrast agent, an exchange of contrast agent between both
compartments is assumed, described by the exchange rate constant
kep, which is closely related to vessel permeability. Another
commonly used functional parameter of the Brix model is the
amplitude A. This parameter reflects the relative change in signal
intensity during contrast media application and is a surrogate
parameter for blood volume.
Statistics
Two-tailed Student’s t-test was used for data analysis, with Po0.05
considered to be statistically significant.
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